Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therapeutics plc was founded in 2014 and is headquartered in London, the United Kingdom.
IPO Year: 2018
Exchange: NASDAQ
Website: autolus.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/18/2024 | $7.00 → $7.60 | Neutral → Buy | Goldman |
| 11/15/2024 | $13.00 | Neutral → Buy | Redburn Atlantic |
| 11/9/2023 | $10.00 | Buy | Deutsche Bank |
| 3/27/2023 | $8.00 | Overweight | Wells Fargo |
| 3/17/2023 | $5.00 | Buy | Bryan Garnier |